



REPLY TO
ATTENTION OF

DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY
820 CHANDLER STREET
FORT DETRICK MD 21702-5014

May 14, 2013

Business Operations Division

Ruben Rene Gonzalez-Perez
Morehouse School of Medicine
Department of Microbiology, Biochemistry, and Immunology
720 Westview Drive SW
Atlanta, GA 30310-1495
rgonzalez@msm.edu

RE: BC123427 - "Targeting Breast Cancer Stem Cells in Triple-Negative Breast Cancer"

STATUS: RECOMMENDED FOR FUNDING

Dear Ruben Rene Gonzalez-Perez:

Congratulations! On behalf of the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP), I am pleased to inform you that the Fiscal Year 2012 (FY12) Breast Cancer Research Program (BCRP) Idea Award application you submitted was recommended for funding. Funding recommendations were made at a second-tier, programmatic review meeting based on program goals and scientific merit. Please note that awards are subject to negotiations and availability of funds. Additional information on the review process is available in the information paper posted under your eReceipt account.

Additional documentation is needed to start the award process. Your timely submission of all applicable documents in the appropriate formats will expedite this process and the release of funds. A CDMRP Science Officer, who will be your scientific and technical point of contact throughout the life of this award, may contact you for further information regarding various aspects of your application. For example, your Science Officer will contact you about Animal Use and Human Use documents that may be needed for your project. Together, you will set a target date for the submission of your complete animal use or human use appendix documents.

A Grants/Contract Specialist from the US Army Medical Research Acquisition Activity (USAMRAA) will contact the Business Official (person authorized to conduct negotiations) at your institution to begin award negotiations. All official negotiations of the budget, terms, and conditions of any resulting award will be limited to the Business Official of your institution and the USAMRAA Grants/Contract Specialist.

Your performance on any previous CDMRP awards will be considered during negotiations. You are advised to review your current and past awards to ensure that all required information has been submitted, including all technical reporting and regulatory oversight documents, as this may impact the negotiation and award process.

If you are withdrawing your application, please co-sign a letter of withdrawal with an administrator from the Sponsored Programs Office at your institution and upload it under the “Required Award Information” tab on the CDMRP eReceipt website (<https://cdmrp.org>).

To expedite the award process, please answer the post-submission questions found under the “Required Award Information” tab on the CDMRP eReceipt website (<https://cdmrp.org>). You and your institution are responsible for ensuring that there is no duplication of the science, budget, or level of effort in separately funded studies in which you were or currently are involved. If you received funding for any portion of this application from another source, or if any portion of the proposed work has already started, please indicate so under this tab.

After providing the information requested under the “Required Award Information” tab, upload or provide the following, for all sites where the DoD-funded work will be conducted, under the “Required Award Documents” tab by May 29, 2013:

- Facility Safety Assurance documents (required only if the institution is not listed as approved at: https://mrmc.amedd.army.mil/assets/docs/sse/Facility_Safety_Plan_Approved_Institutions.pdf)
- Environmental Compliance documents
- Principal Investigator Safety Assurance documents
- Updated details on all existing and pending support for yourself and key personnel, including the title of the project, goals, specific aims/tasks, estimated start date and end date, level of effort (percentage or calendar months) in the project, and point of contact at the funding agency. Provide a cover letter signed by a sponsored programs official, certifying that this information is current and accurate, and addresses any scientific or financial overlap.

A copy of this notification is being made available to your institution’s Sponsored Programs Office.

Again, congratulations on the recommendation of your application for funding. The CDMRP staff and I look forward to working with you to realize the vision of the BCRP, and we encourage you to share the news of your success with your colleagues and the community. Please direct any questions to the CDMRP at help@cdmrp.org or 301-682-5507.

Sincerely,

Wendy A. Baker
Grants Officer



Grant Number: 1R41CA183399-01A1
FAIN: R41CA183399

Principal Investigator(s):
Ruben Rene Gonzalez-Perez, PHD

Project Title: Novel adjuvant therapy for triple negative breast cancer

Lillard, James
President & CEO
Jyant, Inc.
3393 Raes Creek Road
Marietta, GA 300085702

Award e-mailed to: mwilliams@neo-bizsolutions.com

Period Of Performance:

Budget Period: 04/01/2015 – 03/31/2016

Project Period: 04/01/2015 – 03/31/2016

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$225,000 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to JYANT Technologies, Inc. in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 15 USC 638 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R41CA183399. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Alice Chi Wong
Grants Management Officer
NATIONAL CANCER INSTITUTE